Pyrotinib in combination with metronomic oral vinorelbine in patients with HER2positive advanced breast cancer who had failed prior trastuzumab-based therapy: A single-center, single-arm, prospective phase 2 study.

被引：0
|
作者：
Hao, Chunfang [1 ]
Wang, Xu [1 ]
Shi, Yehui [1 ]
Tong, Zhongsheng [1 ]
Li, Shufen [1 ]
Liu, Xiaodong [1 ]
Zhang, Lan [1 ]
机构：
[1] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1033
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Neoadjuvant pyrotinib and inetetamab in combination with chemotherapy for locally advanced HER2-positive breast cancer (NeoPICD study): A prospective, multicenter, open-label, single-arm study.
    Xu, Yiying
    Wu, Xue
    Yang, Chenghui
    Xia, Erjie
    Wang, Yinghao
    Dai, Xuanxuan
    Liu, Haiguang
    Chen, Yizuo
    Wang, Wenqian
    Guo, Guilong
    Wu, Weili
    Li, Xiaoyang
    Wang, Ouchen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [12] Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial
    Jin, Nan
    Xu, Yi
    Wang, Siqi
    Sun, Chunxiao
    Yan, Xueqi
    Yang, Fan
    Liang, Yan
    Chen, Weiwei
    Huang, Xiang
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (01): : 31 - 37
  • [13] A multicenter single-arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
    Shi, Qiyun
    Qi, Xiaowei
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Wang, Shushu
    Liang, Yan
    Hu, Ying
    Wang, Minghao
    Ren, Lin
    Zhang, Guozhi
    Tan, Xuanni
    Yuan, Long
    Du, Junze
    Wu, Xiujuan
    Wang, Mengyuan
    Che, Hongying
    Lv, Pengwei
    Chen, Dejie
    Hu, Jinhui
    Li, Qiuyun
    Zhang, Yanwu
    Yang, Kunxian
    Zhong, Yuan
    Chen, Chuang
    Zhou, Zemin
    Qian, Liyuan
    Zhang, Jingwei
    Ma, Mingde
    Sun, Yi
    Zhang, Yi
    Jiang, Jun
    MEDCOMM, 2023, 4 (06):
  • [14] Pyrotinib combined with metronomic oral etoposide (VP-16) in heavily pretreated HER2-positive metastatic breast cancer: A single-arm, phase II study
    Liu, J.
    He, M.
    Jiang, M.
    Zhou, S.
    Zhang, M.
    Li, Y.
    Chen, S.
    Cai, R.
    Mo, H.
    Lan, B.
    Ma, F.
    Xu, B.
    Li, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S379 - S379
  • [15] Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
    Yan, Min
    Ouyang, Quchang
    Sun, Tao
    Niu, Limin
    Yang, Jin
    Li, Li
    Song, Yuhua
    Hao, Chunfang
    Chen, Zhanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [16] A single-arm phase IIlb study of pertuzumab and trastuzumab with a taxane as first-line therapy for patients with HER2-positive advanced breast cancer (PERUSE)
    Bachelot, T.
    Ciruelos, E.
    Peretz-Yablonski, T.
    Schneeweiss, A.
    Puglisi, F.
    Mitchell, L.
    Dunne, A.
    Miles, D.
    CANCER RESEARCH, 2012, 72
  • [17] Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial
    Shi, Qiyun
    Qi, Xiaowei
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Wang, Shushu
    Zhang, Guozhi
    Wang, Mengyuan
    Che, Hongying
    Lv, Pengwei
    Chen, Dejie
    Hu, Jinhui
    Li, Qiuyun
    Zhang, Yanwu
    Yu, Qiao
    Yang, Kunxian
    Zhong, Yuan
    Chen, Chuang
    Zhou, Zemin
    Qian, Liyuan
    Zhang, Jingwei
    Ma, Mingde
    Sun, Yi
    Liu, Jiangbo
    Zhang, Yi
    Jiang, Jun
    CANCER RESEARCH, 2023, 83 (05)
  • [18] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
    Rupert Bartsch
    Anna Sophie Berghoff
    Julia Furtner
    Maximilian Marhold
    Elisabeth Sophie Bergen
    Sophie Roider-Schur
    Angelika Martina Starzer
    Heidrun Forstner
    Beate Rottenmanner
    Karin Dieckmann
    Zsuzsanna Bago-Horvath
    Helmuth Haslacher
    Georg Widhalm
    Aysegül Ilhan-Mutlu
    Christoph Minichsdorfer
    Thorsten Fuereder
    Thomas Szekeres
    Leopold Oehler
    Birgit Gruenberger
    Christian F. Singer
    Ansgar Weltermann
    Rainer Puhr
    Matthias Preusser
    Nature Medicine, 2022, 28 : 1840 - 1847
  • [19] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
    Bartsch, Rupert
    Berghoff, Anna Sophie
    Furtner, Julia
    Marhold, Maximilian
    Bergen, Elisabeth Sophie
    Roider-Schur, Sophie
    Starzer, Angelika Martina
    Forstner, Heidrun
    Rottenmanner, Beate
    Dieckmann, Karin
    Bago-Horvath, Zsuzsanna
    Haslacher, Helmuth
    Widhalm, Georg
    Ilhan-Mutlu, Aysegul
    Minichsdorfer, Christoph
    Fuereder, Thorsten
    Szekeres, Thomas
    Oehler, Leopold
    Gruenberger, Birgit
    Singer, Christian F.
    Weltermann, Ansgar
    Puhr, Rainer
    Preusser, Matthias
    NATURE MEDICINE, 2022, 28 (09) : 1840 - +
  • [20] AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study
    Dai, Wangshu
    Qiu, Xin
    Lu, Changchang
    Zou, Zhengyun
    Sha, Huizi
    Kong, Weiwei
    Liu, Baorui
    Du, Juan
    FRONTIERS IN ONCOLOGY, 2021, 11
12345